Novo Nordisk's Ozempic successor disappointed Wall Street again

Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street for the second time.

The pharmaceutical giant, known for its blockbuster diabetes drug Ozempic, announced on Monday that patients taking its experimental diabetes and weight-loss drug, CagriSema, lost an average of 15.7% of their body weight after 68 weeks in a phase 3 clinical trial.